Competing risk analysis of events 10 years after revascularization

Scandinavian Cardiovascular Journal

Volumn 44, Issue 5, 2010, Pages 279-288

  Melberg, Tor ^a,c   Nygård, Ottar Kjell ^b,c   Kuiper, Karel Kier Jan ^b   Nordrehaug, Jan Erik ^b,c  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

CABG; Competing risk; Long term survival; PCI

Indexed keywords

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMPETING RISK ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY RECANALIZATION; FEMALE; FOLLOW UP; HEART DEATH; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CAUSE OF DEATH; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; RISK ADJUSTMENT; TREATMENT OUTCOME;

EID: 78649253647     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.3109/14017431003698531     Document Type: Article

References (28)

1. Bravata DM, McDonald KM, Gienger AL, Sundaram V, Perez MV, Varghese R, et al. Comparative effectiveness of percutaneous coronary interventions and coronary artery bypass grafting for coronary artery disease. Comparative Effectiveness Review No. 9. (Prepared by Stanford-UCSF Evidence-based Practice Center under Contract No. 290-02-0017.) Rockville, MD: Agency for Healthcare Research and Quality. October 2007. Available from: http://www. effectivehealthcare.ahrq.gov/reports/fi nal.cfm
2. Sergeant P, Blackstone E, Meyns B, K. U. Leuven Coronary Surgery Program. Validation and interpretation of the infl uence of procedural variables on early and late survival after CABG. Eur J Cardiothorac Surg. 1997;12:1-19.
3. Mack MJ. Clinical trials versus registries in coronary revascularization: Which are more relevant? Curr Opin Cardiol. 2007;22:524-8.
4. Van Domburg RT, Foley DP, Breeman A, der Herwerden LA, Serruys P W. Coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. 20 year outcome. Eur Heart J. 2002;23:543-9.
5. Weintraub WS, Clemens Jr. SD, Crisco V-T, Guyton RA, Craver JM, Jones EL, et al. Twenty-year survival after coronary artery surgery: An institutional perspective from Emory university. Circulation. 2003:107:1271-77.
6. Ford ES, Ajani UA, Croft JB, Critchley JA, Critchley JA, Labarthe DR, et al. Explaining the decrease in U. S. deaths from coronary disease, 1980-2000. NEJM. 2007;356:2388-98.
7. Teirstein PS. The duelling hazards of incomplete revascularization and incomplete data. Circulation. 2006;113:2380-2.
8. Booth J, Clayton T, Pepper J, Nugara F, Flather M, Sigwart U, et al. Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease. Six-year follow-up from the stent or surgery trial (SoS). Circulation. 2008;118:381-8.
9. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefi ned - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefi nition of myocardial infarction. J Am Coll Cardiol. 2000;36:959-69.
10. Lauer MS, Blackstone EH, Young JB, Topol EJ. Cause of death in clinical research. Time for a reassessment? J Am Coll Cardiol. 1999;34:618-20.
11. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized defi nitions. Circulation. 2007;115:2344-51.
12. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Statist Med. 1999;18:695-706.
13. Pintilie M. Competing risks. A practical perspective. Chichester: John Wiley & Sons Ltd.; 2006.
14. Koller MT, Schaer B, Wolbers M, Sticherling C, Bucher HC, Osswald S. Death without prior appropriate implantable cardioverter-defi brillator therapy. A competing risk study. Circulation. 2008;117:1918-26.
15. Albertia C, Metivier F, Landaisc P, Thervet E, Legendre C, Chevret S. Improving estimates of event incidence over time in populations exposed to other events. Application to three large databases. J Clin Epidemiol. 2003;56:536-45.
16. Gooley TA, Leisenring W, Crowley J, Storer B. Why Kaplan-Meier fails and cumulative incidence succeeds when estimating failure probabilities in the presence of competing risks. In: Handbook of statistics in clinical oncology. New York: Marcel Dekker; 2001. pp. 513-23.
17. Ong AT, Serruys PW. Complete revascularization: Coronary artery bypass graft surgery versus percutaneous coronary intervention. Circulation. 2006;114:249-55.
18. Hannan EL, Racz R, Holmes DR, King SB III, Walford G, Ambrose JA, et al. Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. Circulation. 2006;113:2406-12.
19. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper D, Burton JR. Coronary bypass graft fate and patient outcome: Angiographic follow-up of 5065 grafts related to survival and reoperation in 1388 patients during 25 years. J Am Coll Cardiol. 1996;28:616-26.
20. PREVENT IV investigators. Effi cacy and safety of edifogilide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: A randomized controlled trial. JAMA. 2005;294:2446-54.
21. Vikenes K, Andersen KS, Melberg T, Farstad M, Nordrehaug JE. Long-term prognostic value of creatine kinase-myocardial band mass after cardiac surgery in low-risk patients with stable angina. Cardiology. 2009;113:122-31.
22. Steuer J, Granath F, de Faire U, Ekbom A, Ståhle E. Increased risk of heart failure as a consequence of perioperative myocardial injury after coronary artery bypass grafting. Heart. 2005;91:754-8.
23. Gheorghiade M, Sopko G, De Luca L, Velazquez EJ, Parker JD, Binkley PE, et al. Navigating the crossroads of coronary artery disease and heart failure. Circulation. 2006;114:1202-13.
24. Canty JM, Jr. Metabolic and functional consequences of ischemia. In: Libby P. Braunwald ' s heart disease. 8th ed. Ch. 48. Philadelphia: Saunders; 2007.
25. Daemen J, Boersma E, Flather M, Booth J, Stables R, Rodriguez A, et al. Long-term safety and effi cacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: A meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials. Circulation. 2008;118:1146-54.
26. Ebbing M, Bleie Ø, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: A randomized controlled trial. JAMA. 2008;300:795-804.
27. Mølstad P. Survival after percutaneous coronary intervention and coronary artery bypass grafting in a single centre. Scand Cardiovasc J. 2007;41:214-20.
28. Trikalinos TA, Alsheikh-Ali AA, Tatsioni AA, Nallamothu BK, Kent DM. Percutaneous coronary interventions for nonacute coronary artery disease: A quantitative 20-year synopsis and a network meta-analysis. Lancet. 2009;373:911-8.